Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Lung Therapeutics

Lung Therapeutics

Lung Therapeutics is a therapeutics for lung injury and disease company founded in 2013 by Andrew Mazar, Steven Idell and Sreerama Shetty.

Lung Therapeutics is a privately held, clinical stage pharmaceutical company based in Austin, Texas that was founded in 2013 by Andrew Mazar and Steven Idell. It's pursues orphan drug indications for lung injury and disease due to fibrosis for which there are no effective non-surgical options.

Products

The company has two lead product candidates in its pipeline, LTI-01 and LTI-03. They focus on loculated plural effusion and idiopathic pulmonary fibrosis, respectively.

LTI-01

LTI-01 is an injectable, fibrinolytic drug that maximizes scar removal around the lung and thereby promotes fluid drainage while minimizing bleeding risk and other complications. Its active pharmaceutical ingredient is a proenzyme, or zymogen, which slowly becomes activated in the pleural space surrounding the lungs. LTI-01 has received orphan drug designation from both the FDA (2014) and the European Commission (2015) for the treatment of empyema. Phase 1B clinical trials are being conducted at three sites in Australia and New Zealand.

LTI-03

LTI-03 is a drug product that addresses Idiopathic Pulmonary Fibrosis. It is in preclinical development and has shown to resolve bleomycin-induced lung injury. It also has the potential to restore healthy lung function in patients suffering from the disease. In addition, LTI-03 has shown promise in other models of fibrotic diseases.

Funding
Series A

On September 30, 2015 Lung Therapeutics completed their series A funding with $2.6 million in funding from UT Horizon Fund.

Series B

On June 6, 2017 Lung Therapeutics completed their series B funding round with $14.3 million in funding from Bios Partners (lead investor) and UT Horizon Fund.

Timeline

June 4, 2019
Lung Therapeutics raises a $36,000,000 series C round from Bios Partners.
June 2017
Lung Therapeutics raises a $14,300,000 series B round from Bios Partners and UT Horizon Fund.
2013
Lung Therapeutics was founded by Andrew Mazar, Sreerama Shetty and Steven Idell.

Patents

Further Resources

Title
Author
Link
Type
Date

Lung Therapeutics, Inc. Doses First Patient in Phase 1 Clinical Trial of LTI-01 in Australia and New Zealand

Lung Therapeutics, Inc.

Web

Pharma Start-up Lung Therapeutics, Inc. Achieves Significant Funding to Address Unmet Needs in Lung Injury and Disease

Lung Therapeutics, Inc.

Web

News

Title
Author
Date
Publisher
Description
BioSpace
April 13, 2021
BioSpace
The key CSO appointment of Dr. Hogaboam will elevate the company's research and development of new therapeutic applications for the treatment of fibrotic diseases and conditions.

References

Golden logo
By using this site, you agree to our Terms & Conditions.